More Company News

MaxCyte

Development and commercial licence agreement with KSQ Therapeutics
04 Dec 2019Read More

MaxCyte

Clinical and commercial licence agreement with Vor Biopharma
21 Nov 2019Read More

MaxCyte

Phase I with lead CARMA therapy advances to third cohort
24 Oct 2019Read More

MaxCyte

Editas clinical and commercial license agreement
07 Oct 2019Read More

MaxCyte

H119 results
18 Sep 2019Read More

MaxCyte

Trading update
17 Jul 2019Read More

MaxCyte

Capital Markets Day 2019
11 Jul 2019Read More

MaxCyte

CARMA Phase I trial progresses
08 May 2019Read More

MaxCyte

FY18 results
24 Apr 2019Read More

MaxCyte

Launch of ExPERT instrument family
08 Apr 2019Read More

1 2 3 4 5
Return to MaxCyte
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).